Small Intestinal Bacterial Overgrowth (SIBO)

Small intestinal bacterial overgrowth (SIBO) is the presence of an abnormally high bacterial load — historically defined by quantitative culture of jejunal aspirate at greater than 10⁵ colony-forming units (CFU)/mL, a threshold the ACG's 2020 guideline revised downward to 10³ CFU/mL of coliform organisms after studies showed healthy small-bowel fluid typically remains below that lower figure — of colonic-type bacteria within the small intestine, where bacterial density is normally kept low.^[1]

Three host defenses normally keep the small bowel relatively bacteria-sparse: gastric acid, which kills most swallowed organisms before they reach the small intestine; the migrating motor complex (MMC), the cyclical propulsive contraction pattern that sweeps residual bacteria distally into the colon between meals; and the ileocecal valve, which acts as a one-way check valve preventing colonic bacteria from refluxing backward into the small bowel. When gastric acid is suppressed, motility is impaired, or the ileocecal valve is absent or bypassed, bacteria can colonize and persist in the small intestine, ferment dietary carbohydrate prematurely (producing hydrogen and, in a subset of patients, methane), and deconjugate bile acids — the basis of this chapter's symptom picture and, in more advanced cases, its malabsorption findings.^[1]

Typical presentation

Bloating and abdominal distension — often worsening as the day progresses and typically the most prominent complaint — together with excess flatulence, abdominal pain or cramping, nausea, and altered bowel habit. The direction of that bowel-habit change carries real diagnostic weight: hydrogen-predominant (classic) SIBO more often produces watery, non-bloody diarrhea, while methane-predominant disease (intestinal methanogen overgrowth, IMO) more often produces constipation — methane itself has a direct inhibitory effect on small-bowel motility, which is the mechanistic reason for this split and a genuinely useful bedside clue before any breath test is even ordered.^[1]

Malabsorption features in more advanced or longstanding disease

In more chronic or severe cases, bacterial deconjugation of bile acids impairs micelle formation and fat digestion, producing steatorrhea and, over time, deficiency of the fat-soluble vitamins (A, D, E, K). Bacteria also directly consume dietary vitamin B12, while simultaneously synthesizing folate — producing a genuinely distinctive and pharmacist-recognizable laboratory pattern: low or low-normal B12 together with normal or even elevated folate, a combination that should raise SIBO specifically on a differential rather than being read as two unrelated, incidental lab findings. Unintentional weight loss can occur with longstanding, more severe disease, though it is not a typical feature of milder, more common presentations.

Physical examination

Usually unremarkable beyond possible mild distension. A palpable mass, ascites, or focal peritoneal signs are not consistent with uncomplicated SIBO and warrant urgent further assessment rather than being attributed to it (see Red Flags & Refer).

Motility disorders

• Diabetic autonomic neuropathy/gastroparesis — impaired small-bowel motility allows bacteria that would normally be swept distally to persist and multiply.
• Hypothyroidism, through its generalized slowing effect on GI transit.
• Chronic idiopathic intestinal pseudo-obstruction and other primary dysmotility syndromes.
• Parkinson disease, through autonomic/enteric nervous system involvement.
• Chronic opioid therapy — a genuinely modifiable, medication-related contributor: opioids slow GI transit and impair the migrating motor complex, and should be considered specifically in a patient on long-term opioid therapy who develops SIBO-compatible symptoms.

Scleroderma (systemic sclerosis) — a specific, high-prevalence association

Systemic sclerosis is one of the strongest single risk factors identified for SIBO: a 2023 systematic review and meta-analysis found a pooled SIBO prevalence of roughly 40% in systemic sclerosis patients, versus a small fraction of that in matched controls, with a pooled odds ratio around 9.6- to 12-fold depending on the specific analysis.^[3] GI dysmotility from smooth-muscle atrophy and fibrosis is the underlying mechanism — SIBO should be actively considered, not treated as a coincidental finding, in any scleroderma patient with bloating, diarrhea, or worsening GI symptoms.

Structural/anatomic abnormalities

• Prior GI surgery that alters anatomy — Roux-en-Y gastric bypass and other bariatric procedures, small bowel resection creating a blind loop, and, in particular, ileocecal valve resection (e.g., right hemicolectomy) — removing the valve eliminates the one-way barrier that normally prevents colonic bacteria from refluxing into the small bowel, and is one of the most directly mechanistic, surgically explainable causes of SIBO covered in this chapter.
• Small bowel strictures (Crohn disease, radiation enteritis, postoperative adhesions) and small bowel diverticulosis, both of which create areas of relative stasis where bacteria can pool and multiply.

Proton pump inhibitor use — a genuinely important, specific, and modifiable risk factor

Gastric acid is one of the small bowel's primary bacterial defenses, and chronic acid suppression is a real, directly pharmacist-actionable contributor to SIBO risk. A 2013 meta-analysis of 11 studies found PPI use associated with a pooled odds ratio of 2.282 for SIBO (95% CI 1.238-4.205) — but with an important, honestly-reported internal caveat worth passing on rather than smoothing over: the association was strong and clearly significant in the subgroup of studies that used invasive jejunal/duodenal aspirate culture (OR 7.587), but did not reach statistical significance in the subgroup that used glucose hydrogen breath testing (OR 1.93, 95% CI 0.69-5.42) — meaning the true magnitude of PPI-attributable risk is genuinely less certain than the single pooled headline number suggests, and depends partly on which diagnostic method a given study used.^[4] The practical, actionable takeaway for a pharmacist is unchanged despite that nuance: review every chronic PPI for an ongoing, confirmed indication in a patient being worked up for or treated for SIBO (see Choose Initial Treatment and Common Errors to Avoid).

Other predisposing factors

• Achlorhydria/hypochlorhydria from other causes — atrophic gastritis, prior vagotomy, or pernicious anemia.
• Immunodeficiency — selective IgA deficiency, common variable immunodeficiency.
• Chronic pancreatitis/pancreatic exocrine insufficiency, which alters the small-bowel luminal environment.
• Cirrhosis, particularly with portal hypertension and associated dysmotility.
• Advanced age, reflecting a combination of age-related motility decline, polypharmacy (including chronic PPI and opioid use), and higher rates of the structural/surgical risk factors above.

Why SIBO is not simply "IBS with a different name"

The genuine, evidence-hedged overlap between the two

A 2020 systematic review and meta-analysis of case-control studies found SIBO detected significantly more often in patients meeting IBS criteria than in controls — but the pooled estimate varied enormously depending on which diagnostic method the underlying studies used (jejunal aspirate culture versus glucose versus lactulose breath testing), and the authors themselves flagged marked between-study heterogeneity and a real risk of publication bias favouring positive associations.^[2] The honest, clinically useful conclusion from this body of evidence is not "most IBS is actually SIBO" — it is that a real, clinically meaningful minority of patients carrying an IBS label, particularly those with a diarrhea-predominant or mixed pattern, have a genuinely treatable bacterial contributor that is worth actively testing for, especially when standard IBS-directed therapy has been tried and has failed, or when a predisposing condition from Risk Factors is present.

Breath testing — the practical noninvasive diagnostic standard

Quantitative culture of jejunal aspirate (≥10³ CFU/mL of coliform organisms under the revised 2020 threshold) is the technical reference standard, but it requires upper endoscopy, is not widely available, and carries a real risk of contamination from oropharyngeal flora during passage of the aspiration catheter — for these practical reasons, hydrogen/methane breath testing, following the North American Consensus (NAC) technique and interpretation criteria, is the diagnostic approach actually used in clinical practice and the one this guideline endorses as the practical standard.^[1][5]

An emerging third gas, hydrogen sulfide, is increasingly recognized as a contributor to some breath-test-negative, symptomatic patients and is now measurable with newer commercial three-gas breath tests, but validated positivity thresholds for hydrogen sulfide are not yet incorporated into the North American Consensus criteria above — treat this as a genuinely evolving area rather than part of the current diagnostic standard.^[5]

Methane-positive results are not "SIBO with an extra gas" — they define a different entity (IMO)

Methanogens are archaea, biologically distinct from the bacteria that drive classic hydrogen-predominant SIBO, and current terminology increasingly separates intestinal methanogen overgrowth (IMO) as its own entity rather than a subtype of "SIBO" in the strict sense.^[1] This distinction is not academic: methane slows small-bowel transit and is mechanistically linked to constipation rather than diarrhea, and — critically for treatment selection — rifaximin alone is meaningfully less effective against methanogens than against the bacteria of classic SIBO, which is why methane-positive results change the antibiotic regimen (see Choose Initial Treatment).^[6]

An empiric antibiotic trial without formal testing

In a patient with a high pretest probability — most often a clear predisposing cause already identified (a documented motility disorder, surgically altered anatomy with an absent ileocecal valve) — and no access to breath testing, an empiric antibiotic trial is a reasonable, guideline-supported option rather than an absolute requirement to formally test first.^[1]

• Achieve meaningful symptom relief — bloating, gas, pain, and bowel-habit normalization — as the primary, patient-centred goal; breath-test normalization is a reasonable secondary marker but not itself required to call treatment successful.
• Select antibiotic therapy matched to the actual gas pattern (hydrogen-predominant versus methane-positive/IMO) rather than a single default regimen for every patient.
• Identify and address the underlying predisposing cause identified in Risk Factors — this is not an optional add-on but a genuinely essential step for preventing relapse, since antibiotics alone, without addressing the driver, carry a real and well-recognized high relapse rate.
• Correct any identified nutritional deficiency (vitamin B12, fat-soluble vitamins) alongside bacterial eradication.
• Avoid unnecessary, repeated, broad-spectrum systemic antibiotic exposure — favour gut-selective, minimally absorbed agents wherever the clinical picture allows.

Identifying and addressing the underlying predisposing cause — the step most likely to prevent relapse

This is the single most important nonpharmacologic intervention in this chapter, not a secondary consideration after antibiotics. Work through the Risk Factors list with the patient's own history in mind: is there a chronic PPI continued without a confirmed ongoing indication? A diagnosed or suspected motility disorder (diabetes, hypothyroidism, scleroderma) that is itself undertreated? A surgical history that removed the ileocecal valve or created a blind loop? Addressing what is actually modifiable is what separates a durable response from a pattern of repeated retreatment.^[1]

Dietary approaches — genuinely supportive, not primary therapy

• Low-FODMAP diet: restricting fermentable oligo-, di-, and monosaccharides and polyols reduces the substrate available for bacterial fermentation and is a reasonable adjunct for symptom control, best used for a defined trial period with structured reintroduction rather than indefinitely. The evidence specifically in SIBO (as opposed to its considerably better-established role in IBS) remains limited, and at least one recent narrative review raises a genuine, appropriately hedged theoretical concern: restricting fermentable substrate too aggressively or for too long could plausibly deepen an existing dysbiosis rather than correct it, which is a real reason to favour dietitian involvement and a bounded trial over an open-ended restrictive diet.^[8]
• Elemental diet: covered above as an antibiotic alternative; the same practical and evidence-strength caveats apply if used as an adjunct alongside, rather than instead of, antibiotic therapy.^[7]
• Smaller, more frequent meals and allowing genuine fasting intervals between meals support normal migrating motor complex activity, which is itself one of the small bowel's natural anti-bacterial-overgrowth defenses; near-constant grazing can theoretically blunt this cyclical motor pattern.

Nutritional repletion

Replace vitamin B12 and fat-soluble vitamins (A, D, E, K) where deficiency is confirmed, particularly in a patient with a longer symptom duration or evidence of steatorrhea — correcting bacterial overgrowth does not instantly reverse an established deficiency, and repletion should proceed in parallel with, not only after, antibiotic-directed treatment.

Pregnancy and breastfeeding

SIBO itself is not a contraindication to pregnancy. Rifaximin's minimal systemic absorption is reassuring in principle, but dedicated pregnancy/lactation safety data are limited — use only when benefit clearly outweighs uncertainty, and involve the patient's obstetric care team in the decision. Metronidazole is generally considered compatible with pregnancy beyond the first trimester per standard obstetric guidance, and small amounts transfer into breast milk; discuss with the prescriber and obstetric/lactation team rather than defaulting to it reflexively. Neomycin has minimal absorption at gut-directed doses; formal pregnancy-specific SIBO trial data do not exist. Nondrug measures (meal spacing, addressing a modifiable predisposing cause) remain first-line wherever feasible.

Older adults

This is genuinely a high-risk population for SIBO given the cumulative burden of age-related motility decline, chronic PPI use, and prior GI surgery. Malabsorption findings (unintentional weight loss, B12 deficiency, fat-soluble vitamin deficiency) carry real functional and fall-risk consequences in frail older adults and should be actively screened for rather than attributed to "normal aging." Review the full medication list for both PPI and opioid contributors specifically in this group. Reduce the prucalopride starting dose to 1 mg once daily at age 65 and older.

Patients who cannot have the predisposing cause corrected

Not every driver is reversible — a permanently altered surgical anatomy, an absent ileocecal valve, or an irreversible motility disorder cannot simply be "fixed." In these patients, expect a genuinely higher relapse rate despite adequate antibiotic therapy, and consider low-dose prokinetic maintenance (erythromycin or prucalopride) as a reasonable, evidence-limited option to reduce relapse frequency rather than accepting repeated, closely spaced antibiotic courses as the only option.

Scleroderma/systemic sclerosis patients

Given the roughly 40% prevalence and strongly elevated odds ratio in this population, maintain a low threshold to test or empirically treat for SIBO in a scleroderma patient with GI symptoms, and anticipate that recurrence is likely given the underlying, generally non-reversible dysmotility — prokinetic maintenance and periodic retreatment, rather than a single curative course, is the realistic long-term management framework in this group.^[3]

Renal and hepatic impairment

Neomycin requires caution in renal impairment given its aminoglycoside class, even at gut-directed doses with minimal systemic absorption. Metronidazole requires dose reduction in severe hepatic impairment given reduced hepatic clearance. Prucalopride requires the reduced 1 mg dose in severe renal impairment (creatinine clearance 30 mL/min or less) and severe hepatic impairment. Rifaximin needs no adjustment in mild-to-moderate hepatic impairment but should be used cautiously in severe (Child-Pugh class C) impairment given increased systemic absorption in that setting.

Reassess symptom response at the end of the antibiotic course (roughly 2 weeks) rather than leaving follow-up open-ended — genuine benefit is usually apparent by then. Repeat breath testing to confirm normalization is reasonable but not mandatory if the patient is clinically well, since symptom control, not a specific breath-test number, is the primary treatment target.^[1] Reassess and correct any identified nutritional deficiency (B12, fat-soluble vitamins) on an ongoing basis, since repletion can take considerably longer than symptom resolution. At every follow-up, specifically confirm that the predisposing-cause conversation from Choose Initial Treatment actually happened and was actioned — was the PPI indication genuinely reviewed, was a referral for the underlying motility disorder actually made — rather than assuming a single mention at diagnosis was sufficient. Re-screen for new alarm features at any point symptoms change in character, since a stable, previously well-characterized SIBO pattern can still be interrupted by a new, unrelated diagnosis.

1. Confirm the diagnosis and the treatment actually matched the gas pattern found on testing — a methane-positive result treated with rifaximin alone is a common, specifically avoidable cause of apparent treatment failure.
2. Confirm adherence and correct completion of the full antibiotic course before concluding it failed.
3. Reconfirm that the predisposing cause was actually identified and addressed, not just discussed — an unaddressed chronic PPI, an unreferred motility disorder, or an uncorrected anatomic driver is the single most common reason for early relapse after an otherwise adequate antibiotic course.
4. If hydrogen-predominant therapy (rifaximin alone) failed, reconsider whether methane or another gas pattern was actually present, and retest if this was not clearly characterized initially.
5. Retreat with the same regimen if there was an initial response followed by relapse, or switch to the alternate methane-directed combination (rifaximin plus metronidazole in place of rifaximin plus neomycin, or vice versa) if the first combination was inadequate.
6. Consider low-dose prokinetic maintenance (erythromycin or prucalopride) in a patient with a persistent, not-fully-correctable motility driver and a pattern of frequent relapse.
7. Reconsider the diagnosis itself in a patient who has genuinely failed guideline-directed, gas-pattern-matched antibiotic therapy with the predisposing cause addressed — screen for celiac disease, inflammatory bowel disease, or another overlapping condition rather than escalating antibiotic courses indefinitely, and refer to gastroenterology.

• Treating every "IBS-like" presentation as either purely IBS or purely SIBO instead of considering both — particularly in diarrhea-predominant or treatment-refractory presentations, where the evidence for a meaningful SIBO subset is genuine, if imperfect.^[2]
• Using rifaximin alone for a methane-positive result — methanogens respond meaningfully less well to rifaximin monotherapy, and this specific mismatch is a common, avoidable cause of treatment failure.^[6]
• Treating antibiotics as a complete, standalone solution without identifying and addressing the underlying predisposing cause — this is the single most common driver of relapse covered in this chapter.^[1]
• Continuing a chronic PPI indefinitely in a SIBO patient without ever reconfirming the original indication still applies — a broadly under-deprescribed pattern that is directly, specifically relevant here.^[4]
• Missing the low-B12/normal-or-high-folate laboratory pattern as a clue toward SIBO, or attributing it to two unrelated incidental findings.
• Presenting the low-FODMAP diet or the elemental diet as an established, primary cure for SIBO rather than an adjunct or antibiotic-alternative with real but genuinely limited supporting evidence.^[8][7]
• Assuming a positive breath test always requires exhaustive further workup before treatment can start, rather than proceeding directly to gas-pattern-matched antibiotic therapy in a patient without alarm features.
• Overlooking scleroderma, prior GI surgery removing the ileocecal valve, or chronic opioid therapy as specific, worth-asking-about predisposing causes.

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

First-Line — Hydrogen-Predominant (Classic) SIBO

Rifaximin is the only agent with consistent, guideline-preferred trial evidence for SIBO, chosen specifically for its minimal systemic absorption.

First-Line — Methane-Predominant SIBO / Intestinal Methanogen Overgrowth (IMO)

Rifaximin monotherapy is meaningfully less effective against methanogens than against the bacteria of classic SIBO — combination therapy is the guideline-preferred approach for a positive methane result.

Symptomatic Adjunct

Controls stool consistency/urgency only — does not treat the underlying bacterial overgrowth and should not substitute for antibiotic-directed therapy.

Prokinetic Maintenance — Relapse Prevention

Reserve for a patient with a genuine, not-fully-correctable underlying motility driver after eradication is achieved, rather than routine post-treatment use in every patient. Evidence for both agents in this specific role is limited to small trials.

Chronic Acid Suppression — Review for Ongoing Indication

Gastric acid is a primary small-bowel bacterial defense; chronic PPI use is a genuinely important, modifiable SIBO risk factor. None of these are contraindicated outright, but each deserves a specific ongoing-indication review at SIBO diagnosis — see Risk Factors and Choose Initial Treatment. Pooled odds ratio 2.282 (95% CI 1.238-4.205) from a 2013 meta-analysis, with a caveat worth passing on: the association was significant in culture-based studies (OR 7.587) but not in glucose-breath-test-based studies (OR 1.93) within that same pooled analysis.